No Data
Kangwei Century (688426.SH): The human Septin9, SDC2, and NDRG4 gene methylation detection kit has obtained a Class III medical instruments registration certificate.
On March 7, Glonhui reported that Kangwei Century (688426.SH) announced that its wholly-owned subsidiary Jiangsu Jianwei Diagnostic Technology Co., Ltd. (referred to as "Jianwei Diagnostics") independently developed and produced human Septin9, SDC2, and NDRG4 gene methylation detection kits (fluorescent PCR method) has received a Class III "Medical instruments registration certificate" issued by the National Medical Products Administration. As of the date of this announcement, the human Septin9, SDC2, and NDRG4 gene methylation detection kits (fluorescent PCR method) independently developed and produced by Jianwei Diagnostics are the company's first auxiliary diagnostic aids for colorectal cancer.
Kangwei Century: 2024 Annual Results Express Announcement
2024 Annual Results Express Announcement
Kangwei Century (688426.SH) has a net loss of 0.162 billion yuan for the 2024 fiscal year, with overall sales revenue declining.
Kangwei Century (688426.SH) disclosed the performance report for 2024, with the company achieving revenue of 0.128 billion...
Kangwei Century (688426.SH): A total of 2.2774% of shares have been repurchased.
On February 5, Glonghui reported that Kangwei Century (688426.SH) announced that as of the close on January 27, 2025, the company has repurchased a total of 2,561,914 shares through the trading system of the Shanghai Exchange via centralized bidding, accounting for 2.2774% of the company's total share capital of 112,493,716 shares. The highest repurchase price was 25.68 yuan/share, the lowest price was 15.01 yuan/share, and the total amount paid was 47,650,240.73 yuan (excluding stamp duty, trading commission, and other transaction costs).
Kangwei Century: 2024 Annual Results Pre-loss Announcement
Jiangsu CoWin Biotech Co., Ltd.'s (SHSE:688426) 37% Share Price Plunge Could Signal Some Risk